Grifols company profile

GRF · BME · EUR

€11.66Change from previous close: +0.04%Absolute change: +€0.00

Close · November 16, 2026

Company profile

Grifols has 25,000 employees and is headquartered in Barcelona, Spain.

Based in Barcelona, Grifols has been in operation since 1909. The company researches, develops, produces and markets plasma-derived medicines, including albumin, immunoglobulins and thrombin sold to pharma and biotech companies, along with diagnostic testing equipment and reagents, transfusion medicine and clinical diagnostics. Its hospital offering covers intravenous solutions, clinical nutrition, hospital automation systems and medical devices for areas such as interventional neuroradiology, hemodynamics and cardiovascular surgery. Operations span the United States, Canada, Spain, Europe and other markets, organised into the Biopharma, Diagnostic, Bio Supplies and Other segments.

In the fiscal year ended December 2025, Grifols reported revenue of EUR 7.5 billion, up 4.3% from the previous year, and net profit of EUR 402 million. The company employs 25,000 people and has its headquarters in Barcelona, Spain.

Company facts

Industry
Drug Manufacturers - General
Country
Spain
Headquarters
Parque Empresarial Can Sant Joan, 08174, Barcelona
Employees
25,000
Chief executive
Jose Ignacio Abia Buenache
Founded
1909
Fiscal year
January - December
Listing
GRF · BME
Indices
IBEX 35
Currency
EUR
ISIN
ES0171996087

Grifols and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
GrifolsGRFSpain$8.76B25,00018.9%16.4
RecordatiRECItaly$12.11B4,70032.6%21.0
OrionORNAVFinland$15.93B4,21538.1%22.0
VirbacVIRPFrance$3.28B6,44215.8%19.1
BayerBAYNGermany$61.37B87,77516.5%—
GSKGSKUnited Kingdom$101.36B66,84130.5%17.9

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Grifols with its competitors